AMRN – Running Up To The AdCom

Amarin Corporation plc (AMRN) -Nasdaq The price closed above the 100-Day moving avarage and the $6.34 resistance line, while the indicators still positive and wants more upside. The next important line to.

PGNX – A Hidden Bullish Divergence

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq On June 11, 2013 Progenics and Salix (partner) announced an FDA Advisory Committee (AdCom) is scheduled to review Relistor sNDA for opioid-induced constipation(OIC) in patients with.

IBB – Technical Commentary

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolio are the biotechnology indices IBB, NBI, XBI or XLV. After publishing “IBB – Biotechnology Index at All Times.

ASTX – Breaking out of the Downtrend Channel

Astex Pharmaceuticals, Inc. (ASTX)  -Nasdaq ASTX had an epic run that started at the end of February from the low of $2.94, just after two months of price consolidation, and reached.

BMY – In A Consolidation Mode

Bristol-Myers Squibb Company (NYSE: BMY) BMY had an amazing run ahead of ASCO-2013 that left many well-planned traders very happy. The stock found strong support near the 50-Day Moving Average.

SRPT – Sarepta – Is It The Time For A New High?

Sarepta Therapeutics, Inc – Nasdaq(SRPT) Sarepta is one of the most followed tickers in twitterville with a real bulls/bears debate. It has strong moms’ advocacy groups fighting full strength to get.

IBB – Biotechnology Index at All Times High

Nasdaq Biotechnology Index Fund ETF (IBB) The best indicator for our biotech portfolio are the biotechnology indexes like IBB, NBI, XBI or XLV. Since we already published “The IBB and.

DCTH – Soaring Ahead of The Upcoming Advisory Committee

Delcath Systems, Inc. (DCTH) -Nasdaq DCTH has been on our watch list for a while, looking for an entry point. we kept following out the stock performance at the forum and.

XNPT – It’s Time to Join The Run To The Ph-3 Resutls

Xenoport, Inc. (XNPT) -Nasdaq Lately, the reals runner were those with pending clinical trial data, where we saw TSRX and ZIOP’s share price move much more than the PDUFA runners..

SGMO – Is it The Time For a Correction

Sangamo Biosciences Inc. (SGMO) -Nasdaq Within three months the share price of SGMO doubled, soaring from the $5.50 area and reaching a new 5 years high of  $11.24, getting a.

DEPO – Action Ahead Of The AdCom

DepoMed Inc. (DEPO) -Nasdaq Serada is an investigational formulation of gabapentin, an FDA-approved immediate release pharmaceutical for the treatment of partial epilepsy and management of postherpetic neuralgia (PHN). Recently published.

SRPT – Preparing For The Next Move

Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is a biotech company under the spotlights since early October 2012, after presenting strong Phase IIb results for the compound Eteplirsen in the treatment of.

ARRY – Is It Ready For The Next Move

Array BioPharma, Inc. (ARRY)-Nasdaq As a technical analyst I’m looking for patterns and throughout the years I’ve found that stock patterns show that more often than not history repeats itself..

The IBB and SPX In The Decision Zone

In my previous report “IBB – A Closer Look at the Market’s Direction” I tried to find out if the markets bottomed out after the technical correction in the indices.

ONTY – Preparing For The Next Move

Oncothyreon Inc (ONTY)-Nasdaq Oncothyreon’s getting a lot of attention ahead of its near term catalyst set for Q1 2013 with the final analysis of its pivotal START trial. Results expected.

CLDX – A Positive Divergence Case

Celldex Therapeutics, Inc. (CLDX)-Nasdaq CLDX’s chart is one of a kind and very easy to understand even by a novice chart technician. It has been repeating the same moves, creating.

Browsing 16 / 56 articles